Long-Term Treatment With Apremilast in Hidradenitis Suppurativa: A 2-Year Follow-Up of Initial Responders

The study followed initial responders from a randomized controlled trial of apremilast for hidradenitis suppurativa (HS) over 2 years. Initially, 53.3% of patients met the Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 weeks of treatment. Of the 8 initial responders, 4 continued treatment for 2 years, all achieving HiSCR at follow-up visits. Two patients discontinued due to pregnancy wishes, and others due to side effects or symptom remission. Despite manageable side effects, 75% of participants would recommend apremilast. The study suggested prolonged efficacy of apremilast for HS, but emphasized the need for larger studies to confirm long-term benefits.